Financials

Company Profile

Scorpius Holdings, Inc. is not engaged in any business activities. The Company was previously a contract development and manufacturing organization.

Employees

Sector

Date	Price	Change	Volume
26-08-13	US$0.001000	-16.67%	12,401

Real-time OTC Markets

Market Closed - OTC Markets 10:29:25 2026-06-03 EDT			5-day change	1st Jan Change
0.001400 ^USD	+7.69%		+16.67%	+600.00%

04-24	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
04-08	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI

04-24	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
04-08	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI
03-10	Scorpius Holdings, Inc. announced that it has received $0.031175 million in funding	CI
02-25	Scorpius Holdings, Inc. announced that it has received $0.219544 million in funding	CI
02-17	Scorpius Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
02-11	Scorpius Holdings, Inc. announced that it has received $0.030427 million in funding	CI
01-12	Scorpius Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12-15	Scorpius Holdings, Inc. announced that it has received $0.044374 million in funding	CI
12-10	Velocity Bioworks, Inc. acquired All of Personal Property and Assets of Scorpius Holdings, Inc. for $16.3 million.	CI
12-02	Scorpius Holdings, Inc. Announces Issuance of Multiple Non-Convertible Promissory Notes with Customary Terms	CI
11-30	Scorpius Holdings, Inc. announced that it has received $0.1541 million in funding	CI
11-25	Scorpius Holdings, Inc. announced that it has received $0.724523 million in funding	CI
11-24	Scorpius Holdings, Inc. announced that it has received $0.03795 million in funding	CI

23-05-01	Brookline Capital Downgrades NightHawk Biosciences to Hold From Buy	MT
23-04-03	Maxim Downgrades NightHawk Biosciences to Hold From Buy	MT
22-03-18	B. Riley Lowers Heat Biologics' PT to $8 from $10, Adjusts Model for Higher Cost of Capital to Support Higher Operating Expenditures Ramp; Keeps Buy Rating	MT
22-03-15	Alliance Global Adjusts Heat Biologics' Price Target to $15.50 From $20, Reiterates Buy Rating	MT
22-01-24	B. Riley Lowers Heat Biologics' Price Target to $10 from $15 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT

01-12	Scorpius : Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)	PU
24-11-14	Scorpius : Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability Form 8 K	PU
24-10-22	Scorpius Holdings Announces Partnership with U.S. Biotech Company	AQ
24-10-02	Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats	AQ
24-09-30	Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities	AQ

Manager	Title	Age	Since
Jeff Wolf CEO	Chief Executive Officer	63	2010-03-31
Joe Payne COO	Chief Operating Officer	-	-
David Waldman IRC	Investor Relations Contact	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/16/24	Jeff Wolf	Free	Chief Executive Officer	5,000,000	13.8766%
5/16/24	Seed-One Ventures LLC	Other	Company	0	0%
5/16/24	Orion Holdings LLC	Other	Company	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCORPIUS HOLDINGS, INC.	+7.69%	+16.67%	-87.27%	-100.00%	73.37K
CHURCHILL CAPITAL CORP XI	0.00%	-1.28%	-	-	902M
CENTIEL AG	+3.20%	+3.80%	+317.65%	-68.30%	692M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	+0.20%	-	-	645M
CHURCHILL CAPITAL CORP XII	-0.19%	+0.05%	-	-	604M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.10%	+0.39%	-	-	598M
CANTOR EQUITY PARTNERS IV, INC.	+0.10%	+0.29%	-	-	596M
KEYSTONE ACQUISITION CORP.	+0.10%	+0.30%	-	-	583M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.43%	-0.26%	-	-	574M
Average	+1.29%	+0.03%	+115.19%	-84.15%	577.01M
Weighted average by Cap.	+0.56%	-0.02%	+317.60%	-68.31%